WO2000015176A3 - Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities - Google Patents

Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities Download PDF

Info

Publication number
WO2000015176A3
WO2000015176A3 PCT/US1999/020645 US9920645W WO0015176A3 WO 2000015176 A3 WO2000015176 A3 WO 2000015176A3 US 9920645 W US9920645 W US 9920645W WO 0015176 A3 WO0015176 A3 WO 0015176A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
treatment procedure
procedure
squalamine
cytotoxic chemical
Prior art date
Application number
PCT/US1999/020645
Other languages
French (fr)
Other versions
WO2000015176A2 (en
Inventor
Michael Zasloff
Jon Williams
Mitchell H Sokoloff
Original Assignee
Magainin Pharma
Michael Zasloff
Jon Williams
Mitchell H Sokoloff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Pharma, Michael Zasloff, Jon Williams, Mitchell H Sokoloff filed Critical Magainin Pharma
Priority to JP2000569761A priority Critical patent/JP2002524481A/en
Priority to EP99952905A priority patent/EP1119361A4/en
Priority to AU64962/99A priority patent/AU757649B2/en
Priority to CA002343133A priority patent/CA2343133A1/en
Publication of WO2000015176A2 publication Critical patent/WO2000015176A2/en
Publication of WO2000015176A3 publication Critical patent/WO2000015176A3/en
Priority to US09/803,740 priority patent/US6596712B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for treating a tumor includes a first treatment procedure using a conventional cancer treatment technique, and a second treatment procedure which includes administering an effective amount of squalamine. Synergistically effective amounts are preferred. The first treatment procedure may be a treatment with one or more conventional cytotoxic chemical compounds. As examples, the cytotoxic chemical compound may be a nitrosourea (such as BCNU), cyclophosphamide, doxorubicin, 5-fluorouracil, paclitaxel and its derivatives, cisplatin or other platinum containing cancer treating agents. Alternatively, the first treatment may be a treatment with one or more conventional anti-hormonal agents. As examples, the anti-hormonal agents may be a LHRH (luteinizing hormone releasing hormone) agonist or an anti-androgen such as flutamide, biclutamide, nilutamide, and luprolide. These conventional cancer treatments compounds and the squalamine may be administered by any suitable route. The first treatment procedure may take place prior to the second treatment procedure, after the second treatment procedure, or the two treatment procedures may take place simultaneously. As an alternative, the first treatment procedure may be a conventional radiation treatment regimen. As a further alternative the first treatment procedure may be a combination of treatment with one or more conventional cytotoxic chemical compounds and a conventional radiation treatment regimen.
PCT/US1999/020645 1996-04-26 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities WO2000015176A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000569761A JP2002524481A (en) 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anticancer drugs or physiotherapy
EP99952905A EP1119361A4 (en) 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
AU64962/99A AU757649B2 (en) 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
CA002343133A CA2343133A1 (en) 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US09/803,740 US6596712B2 (en) 1996-04-26 2001-03-12 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15072498A 1998-09-10 1998-09-10
US09/150,724 1998-09-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15072498A Continuation-In-Part 1996-04-26 1998-09-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/803,740 Continuation US6596712B2 (en) 1996-04-26 2001-03-12 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities

Publications (2)

Publication Number Publication Date
WO2000015176A2 WO2000015176A2 (en) 2000-03-23
WO2000015176A3 true WO2000015176A3 (en) 2000-07-20

Family

ID=22535747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/020645 WO2000015176A2 (en) 1996-04-26 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities

Country Status (5)

Country Link
EP (1) EP1119361A4 (en)
JP (1) JP2002524481A (en)
AU (1) AU757649B2 (en)
CA (1) CA2343133A1 (en)
WO (1) WO2000015176A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040835A1 (en) * 1996-04-26 1997-11-06 Magainin Pharmaceuticals Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents
US5721226A (en) * 1993-03-10 1998-02-24 Magainin Pharmaceuticals Inc. Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
JPS6133121A (en) * 1984-07-25 1986-02-17 Nissei Marine Kogyo Kk Carcinostatic
DE19606355A1 (en) * 1996-02-12 1997-08-14 Schering Ag Contraceptive release systems with antiviral and / or antibacterial effects

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721226A (en) * 1993-03-10 1998-02-24 Magainin Pharmaceuticals Inc. Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives
WO1997040835A1 (en) * 1996-04-26 1997-11-06 Magainin Pharmaceuticals Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RES., vol. 18, no. 4A, 1998, pages 2567 - 2573 *
DATABASE CAPLUS ON STN "Treatment of tumors using squalamine in combination with other anticancer agents or radiation" *
DATABASE CAPLUS ON STN TEICHER ET AL.: "Potential of the Aminosterol, Squalamine in Combination Therapy in the Rat" *
See also references of EP1119361A4 *

Also Published As

Publication number Publication date
EP1119361A4 (en) 2006-10-04
EP1119361A2 (en) 2001-08-01
AU6496299A (en) 2000-04-03
CA2343133A1 (en) 2000-03-23
JP2002524481A (en) 2002-08-06
WO2000015176A2 (en) 2000-03-23
AU757649B2 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
CA2252584A1 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents
Hortobagyi et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer
WO2002056864A3 (en) Differential delivery of nitric oxide
Ferry et al. Busulfan-cyclophosphamide versus total body irradiation–cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned?
NI200400014A (en) ARILUREA COMPOUNDS IN COMBINATION WITH OTHER CITOSTATIC OR CYTOTOXIC AGENTS TO TREAT HUMAN CANCER
CA2450942A1 (en) Method of treating hyperproliferative diseases using active vitamin d analogues
Mayer et al. Complications of irradiation related to apparent drug potentiation by adriamycin
JP2004535429A5 (en)
WO2005037928A3 (en) Compounds for dual photodiagnosis and therapy
Dobelbower Jr et al. Pancreatic carcinoma treated with high‐dose, small‐volume irradiation
JPS5735516A (en) Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
Khuntia et al. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors
WO2000015176A3 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
Pouillart et al. Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trial
Keizer et al. Ifosfamide treatment as a 10-day continuous intravenous infusion
Dewit et al. Influence of cis-diamminedichloroplatinum (II) on mouse duodenal crypt stem cell survival after multifraction X ray treatment
JP2006528696A (en) Method for enhancing antitumor activity of anticancer agent
BR0214564A (en) Cancer Treatment Processes Using a Fpt Inhibitor and Antineoplastic Agents
WO2006078903B1 (en) Radiosensitizer formulations comprising nitrohistidine derivatives
Hansen et al. High activity of mitoxantrone in previously untreated low-grade lymphomas
Park et al. Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors
Chu et al. Radiosensitizers and protectors
Holte et al. Chlvpp is as Effective as Alternating ChlvppAbod in Advanced Stage Hodgkin's Disease
Possinger et al. Oral administration of idarubicin as first line cytostatic therapy in patients with metastasized breast cancer and favourable prognosis: A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 64962

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2343133

Country of ref document: CA

Ref country code: CA

Ref document number: 2343133

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 569761

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09803740

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 64962/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999952905

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999952905

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 64962/99

Country of ref document: AU